Bosutinib, a Src/c-Abl inhibitor, boosted autophagy, reduced the amount of misfolded mutant SOD1 proteins, and attenuated the altered expression of mitochondrial genes, while also increasing the in vitro survival of ALS iPSC-derived motor neurons from patients with other forms of ALS, including sporadic ALS and other forms caused by mutations in other genes. The gene discussed is SRC; the disease is amyotrophic lateral sclerosis.